+7 (701) 759 90 19
USD 426.77 EUR 509.95
RUB 5.89 CNY 66.34
News

Pfizer vaccine effective against COVID-19 variants in Japan: study

12 May 2021 21:34
Share in:
Pfizer vaccine effective against COVID-19 variants in Japan: study

TOKYO. KAZINFORM - Around 90 percent of those who received the vaccine developed by U.S. pharmaceutical giant Pfizer Inc. were found to have antibodies against the various COVID-19 variants detected in Japan, a university study showed Wednesday, Kyodo reports.

Related news
Kazakhstan’s daily COVID-19 case count stands at 1,174 S. Korea to begin inoculating younger population in July, allow 'mix and match' jabs Over 300 treated for COVID-19 at healthcare facilities in Atyrau region

The study by a research team at Yokohama City University was conducted on 105 people who had received both doses of the vaccine without contracting the novel coronavirus and covered seven variants.

Of the 105 people, 90 to 94 percent were found to have antibodies against the variants found in Britain, South Africa and Brazil, while 97 percent had antibodies against the variant detected in India, the study showed.

It also found that 99 percent had antibodies against the coronavirus present from the start of the outbreak in Japan.

Japan is now facing a fourth wave of infections amid the spread of more contagious variants, while its vaccine rollout is lagging behind other countries, such as Britain, Israel and the United States.

The vaccine developed by Pfizer and German partner BioNTech SE is currently the only one authorized for use in Japan.



Share in:
Related news
Read also
+7
Send
Employees online
Editor
Nurmaganbetova Zhanna
Nurmaganbetova Zhanna
954-048
Editor
Kudrenok Tatyana
Kudrenok Tatyana
954-048
Editor
Seilkhanov Adlet
Seilkhanov Adlet
954-048

Archive